{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-048001","form_type":"8-K","ticker":"IXHL","cik":"0001873875","company_name":"Incannex Healthcare Inc.","filed_at":"2025-05-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.323430+00:00","generated_at":"2026-05-20T08:45:30.820952+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Incannex cancels 172M Series A warrants, eliminating up to 347.2M shares from dilution","bullets":["Agreement to cancel remaining 172M Series A warrants; cancellation payment up to $12.2M.","Combined with earlier cancellation (175.2M), total elimination of up to 347.2M potential shares.","Move ahead of Phase 2 RePOSA trial data for IHL-42X in sleep apnea expected July 2025.","CEO Joel Latham cites strengthening capital structure and proactive dilution management."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-048001","json":"https://secwatch.observer/filing/0001213900-25-048001.json","markdown":"https://secwatch.observer/filing/0001213900-25-048001.md","text":"https://secwatch.observer/filing/0001213900-25-048001.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1873875/000121390025048001/0001213900-25-048001-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1873875/000121390025048001/ea0243460-8k_incannex.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T08:45:30.820952+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}